Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts

Respiratory Research

Table 2 Univariate associations of thrombocytosis (platelet count ≥350 × 10⁹/L) with COPD morbidity

Outcomes [% or mean ± standard deviation]	SPIROMICS			COPDGene
Outcomes [% or mean ± standard deviation]	Platelet Count <350 × 10⁹/L	Platelet Count ≥350 × 10⁹/L	p-value	Platelet Count <350 × 10⁹/L	Platelet Count ≥350 × 10⁹/L	p-value
Any Acute Exacerbation of COPD during the prior year	30.7%	43.6%	0.003*	27.5%	37.8%	0.02*
Severe Acute Exacerbation of COPD during the prior year	15.5%	24.2%	0.01*	14.6%	23.4%	0.01*
Modified Medical Research Council (mMRC) Questionnaire score ≥ 2	31.4%	47.5%	0.0002*	52.9%	64%	0.02*
COPD Assessment Test (CAT) score ≥ 10	72.4%	86.2%	0.001*	66.4%	77.5%	0.02*
GOLD symptom group D	20%	33%	0.0009*	19.4%	33.3%	0.0004*
6-min walk distance in meters	395 ± 128	352 ± 134	0.007^a	371 ± 124	358 ± 118	0.3^a
St. George Respiratory Questionnaire score	38 ± 20	44 ± 19	0.0002^a	32 ± 22	38 ± 24	0.005^a

GOLD Global Initiative for Chronic Obstructive Lung Disease. *chi-squared test; ^at-test

ISSN: 1465-993X